Abcellera Biologics Inc is trading 7.9% up at $6.17 as investors position themselves ahead of the company's scheduled appearance at the Jefferies Global Healthcare Conference.
- The stock is rebounding after two consecutive down sessions, with market participants viewing the upcoming presentation as a potential catalyst for updates regarding its pipeline and strategic partnerships.
- Buying interest is driven by expectations for new insights into the company's development milestones and long-term growth trajectory.